NCT02913924View on ClinicalTrials.gov

Effect of Clonazepam on Cannabis Withdrawal and Relapse in Treatment-seeking Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

June 30, 2020

Study Completion Date

June 30, 2020

Conditions
Cannabis Use Disorder
Interventions
DRUG

Clonazepam

fixed-flexible daily dose to a maximum of 2 mg (1 mg twice per day) for the first 8 weeks of the trial

DRUG

Placebo

Trial Locations (1)

10032

Substance Treatment Research Service (STARS) of Columbia University, New York

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

New York State Psychiatric Institute

OTHER

NCT02913924 - Effect of Clonazepam on Cannabis Withdrawal and Relapse in Treatment-seeking Patients | Biotech Hunter | Biotech Hunter